Sign in

EPRX on Nasdaq

EUPRAXIA PHARMACEUTICALS INC.

EUPRAXIA PHARMACEUTICALS INC. is a Canadian pharmaceutical preparations company based in Victoria.2 Its shares trade on Nasdaq under the symbol EPRX.2

Price unavailable

Last updated Oct 21, 2026.

Overview

$0Revenue, fiscal 20253
-$38.6MNet income, fiscal 20253

Compare with another stock.

  • TickerEPRX on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersVancouver, Canada2
  • Incorporated inBritish Columbia, Canada4
  • Business address2198 Yukon Street, Vancouver, V5Y 3P14
  • Filer category, Emerging growth company4
  • Legal formCorporation2
  • LEI254900ABKL5YBZMSYH452
  • StatusActive2
  • LEI statusIssued and current2
  • Registered address1500 Royal Centre, V6E 4N7 Vancouver, Canada2
  • Registered withBC Registry Services, 8187173082

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-47.0%Return on equity3

Financial statements

Revenue563$0 in 2025
02023: $0$020232024: $0$020242025: $0$02025
Net income563-$38.6M in 2025+109% since 2022
-$40.0M-$30.0M-$20.0M-$10.0M02022: -$18.5M-$18.5M20222023: -$28.2M-$28.2M2023+53%2024: -$25.5M-$25.5M2024−10%2025: -$38.6M-$38.6M2025+51%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
General and administrative$17.1M$10.9M
Research and development$21.3M$16.1M
Total expenses$38.4M$27.0M
Interest income$1.4M$1.2M
Interest expense$0-$603.6K
Gain (loss) on sale of equipment-$2.6K$18.6K
Foreign exchange gain (loss)-$1.6M-$159.2K
Convertible debt costs$0-$355.6K
Change in fair value of financial instruments$0$1.2M
Total other income/(loss)-$152.5K$1.3M
Loss before tax expense-$38.6M-$25.7M
Tax expense-$19.1K-$1.8K
Owners of the Company-$38.6M-$25.5M
Non-controlling interest-$29.5K-$242.0K
Net loss for the year-$38.6M-$25.7M
Foreign currency translation adjustment$2.1M-$1.5M
Comprehensive loss for the year-$36.5M-$27.2M
Loss per share basic-$1.03-$0.76
Loss per share diluted-$1.03-$0.76
Weighted average shares outstanding basic40.0M shares33.9M shares
Weighted average shares outstanding diluted40.0M shares33.9M shares

Compare EUPRAXIA PHARMACEUTICALS INC. with another company

Corporate structure

EUPRAXIA PHARMACEUTICALS INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of EUPRAXIA PHARMACEUTICALS INC.

  • MANCHESTER MANAGEMENT CO LLC Filed SCHEDULE 13G/A on EUPRAXIA PHARMACEUTICALS INC., latest Aug 13, 2026 (4 filings since Nov 13, 2025)
  • Joseph S. Freedman Filed SCHEDULE 13D/A on EUPRAXIA PHARMACEUTICALS INC., latest Mar 16, 2026 (3 filings since Nov 7, 2024)
  • Beutel, Goodman & Co Ltd. Filed SCHEDULE 13G on EUPRAXIA PHARMACEUTICALS INC., latest Nov 14, 2025
  • Robert Disbrow Filed SCHEDULE 13G/A on EUPRAXIA PHARMACEUTICALS INC., latest Nov 14, 2025 (2 filings since Nov 14, 2024)
  • EUPRAXIA PHARMACEUTICALS INC. Vancouver, British Columbia, Canada

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What EUPRAXIA PHARMACEUTICALS INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.5M3 Dec 31, 2025$817.6K3 Dec 31, 2024+80.8%
Accumulated depreciation$644.2K3 Dec 31, 2025$459.7K3 Dec 31, 2024+40.1%
Property and equipment, net$834.4K3 Dec 31, 2025$357.9K3 Dec 31, 2024+133.2%
Operating-lease assets (leased space)$152.7K3 Dec 31, 2025$67.0K3 Dec 31, 2024+127.8%

Real estate and locations

ItemLatestA year beforeChange
Area of real estate4,900 sq ft3 Dec 31, 20254,900 sq ft6 Dec 31, 20240%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$80.6M3 Dec 31, 2025$33.1M3 Dec 31, 2024+143.4%

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerAmanda Malone named Aug 22, 2023 to Nov 8, 20247
  • Executive OfficerBruce Cousins named Aug 22, 2023 to Nov 8, 20247
  • Executive Officer, DirectorJames Helliwell named Aug 22, 2023 to Nov 8, 20247
  • Executive OfficerMark Kowalski named Aug 22, 2023 to Nov 8, 20247
  • Executive OfficerPaul Brennan named Aug 22, 2023 to Nov 8, 20247
  • Executive OfficerRahul Sarugaser named Nov 8, 20247
  • DirectorJohn Montalbano named Aug 22, 2023 to Nov 8, 20247
  • DirectorJoseph Freedman named Nov 8, 20247
  • DirectorMichael Wilmink named Aug 22, 2023 to Nov 8, 20247
  • DirectorPaul Geyer named Aug 22, 2023 to Nov 8, 20247
  • DirectorRichard Glickman named Aug 22, 2023 to Nov 8, 20247
  • DirectorSimon Pimstone named Aug 22, 2023 to Nov 8, 20247

Timeline

  1. May 11, 2012Founded EUPRAXIA PHARMACEUTICALS INC. is founded2

Calendar

Coming up

  1. Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.19) a share, on Nov 4, 2025.8

Drug trials and FDA: coming up

  1. Dec 2026Phase 1/2 trial readout expected Phase 1/2 trial of EP-104GI in Eosinophilic Esophagitis: primary completion expected Dec 2026 (ClinicalTrials.gov NCT05608681).9

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

119 filings to the SEC since October 2021: 3 annual reports, 10 large holders, 2 private raises, 104 other. The latest 20:

  1. Oct 15, 20266-K EDGAR
  2. Oct 9, 20266-K EDGAR
  3. Sep 30, 20266-K EDGAR
  4. Sep 8, 20266-K EDGAR
  5. Sep 2, 2026SUPPL EDGAR
  6. Aug 24, 2026EFFECT EDGAR
  7. Aug 19, 2026F-10/A EDGAR
  8. Aug 13, 20266-K EDGAR
  9. Aug 13, 2026SCHEDULE 13G/A EDGAR
  10. Aug 11, 20266-K EDGAR
  11. Aug 6, 2026F-X EDGAR
  12. Aug 6, 2026F-10 EDGAR
  13. Jul 15, 20266-K EDGAR
  14. Jul 13, 20266-K EDGAR
  15. Jul 7, 20266-K EDGAR
  16. Jun 22, 20266-K EDGAR
  17. May 29, 20266-K EDGAR
  18. May 29, 20266-K EDGAR
  19. May 28, 20266-K EDGAR
  20. May 12, 20266-K EDGAR

The 119 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$2.0M 2023–2024
Money received by yearMoney received by year, 2023–2024: $2.0M in all. Private raises (Form D) $2.0M.$0$500K$1M$1.5M$2M2023 · Private raises (Form D): $128.4K20232024 · Private raises (Form D): $1.9M2024
Figures by year
YearPrivate raises (Form D)Total
2024$1.9M$1.9M
2023$128.4K$128.4K

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Oct 31, 2024Raised $1.9 million in a private offering of equity7 Form D: 6 investors so far Form D
  2. Aug 18, 2023Raised $128,394 in a private offering of equity14 Form D: 3 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 68. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Affinity Asset Advisors, LLC1,650,000$10.9M0.5%+60,995
Balyasny Asset Management L.P.1,350,015$8.9M0.0%+15
Vivo Capital, LLC1,350,000$8.9M0.8%No change
Scotia Capital Inc.1,343,726$8.8M0.0%+1,548
PFM Health Sciences, LP1,210,661$8.0M0.7%+669,790
Great Point Partners LLC1,200,000$7.9M1.9%No change
Jupiter Topco LLC1,046,000$6.9M0.0%New
Rubric Capital Management LP867,424$5.7M0.1%+176,254
Ikarian Capital, LLC809,741$5.4M0.9%−405,000
Woodline Partners LP746,864$4.9M0.0%+306,313
Point72 Asset Management, L.P.730,284$4.8M0.0%−237,291
Ameriprise Financial Inc711,024$4.7M0.0%+61,950
Redmile Group, LLC611,400$4.0M0.3%−88,600
Seven Fleet Capital Management LP610,785$4.0M0.7%+177,270
UBS Group AG519,211$3.4M0.0%−243,424
Citadel Advisors LLC502,011$3.3M0.0%+271,835
Millennium Management LLC441,586$2.9M0.0%New
Alyeska Investment Group, L.P.375,000$2.5M0.0%No change
Picton Mahoney Asset Management360,878$2.4M0.0%New
Velan Capital Investment Management LP352,000$2.3M1.4%No change
Jane Street Group, LLC329,053$2.2M0.0%+293,843
Aisling Capital Management LP325,000$2.1M0.5%No change
SummitTX Capital, L.P.318,784$2.1M0.1%−9,213
Royal Bank Of Canada311,435$2.1M0.0%+50,059
Dv Equities, LLC276,000$1.8M0.3%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How EUPRAXIA PHARMACEUTICALS INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAREUPRAXIA PHARMACEUTICALS INC.1
  • CIK0001581178
  • Filer status<br>emerging growth company an emerging growth company1
  • Incorporated inBritish Columbia15
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address2198 Yukon Street, Vancouver, V5Y 3P1, British Columbia, Canada1
  • Phone250-590-39681
  • Shares outstanding51,939,206 Common Shares shares; 8,355,638 Preferred Shares shares as of Dec 31, 202515
  • AuditorKPMG LLP, Vancouver, Canada PCAOB ID 85; no auditor attestation of internal control over financial reporting15
  • On EDGAR sinceJul 11, 20131
  • Filings125 in all: 6-K (87), D (8), SUPPL (5), SCHEDULE 13G/A (4), 40-F (3), EFFECT (2), F-10 (2), F-10/A (2)1
    All 16 form types

    F-X (2), S-8 (2), SCHEDULE 13D/A (2), SCHEDULE 13G (2), 8-A12B (1), CERT (1), SC 13D (1), SC 13G (1)

  • Latest filingsAnnual report (40-F) Mar 13, 2026

Securities registered for trading

ClassSymbolExchange
Common Shares, no par valueEPRXThe Nasdaq Stock Market LLC

From the cover page of the 40-F filed Mar 13, 2026 (Section 12(b) of the Exchange Act).15

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15